JD Vance Predicts: Wall Street vs. Trump & Your Money

Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.

Get your free guide NOW before it's too late.

Francisco Silva Biography and Net Worth

VP of BioRestorative Therapies

Secretary, Director & VP-Research & Development

What is Francisco Silva's net worth?: The estimated net worth of Francisco Silva is at least $208,822.60 as of April 8th, 2024. Mr. Silva owns 149,159 shares of BioRestorative Therapies stock worth more than $208,823 as of November 21st. This net worth approximation does not reflect any other assets that Mr. Silva may own. Additionally, Mr. Silva receives a salary of $891,670.00 as VP at BioRestorative Therapies. Learn More about Francisco Silva's net worth.
How old is Francisco Silva?: Mr. Silva is currently 49 years old. There are 3 older executives and no younger executives at BioRestorative Therapies. The oldest executive at BioRestorative Therapies is Mr. Robert Eugene Kristal, Chief Financial Officer, who is 56 years old. Learn More on Francisco Silva's age.
What is Francisco Silva's salary?: As the VP of BioRestorative Therapies, Inc., Mr. Silva earns $891,670.00 per year. The highest earning executive at BioRestorative Therapies is Mr. Lance Alstodt, Chairman of the Board, President & CEO, who commands a salary of $954,170.00 per year. Learn More on Francisco Silva's salary.
How do I contact Francisco Silva?: The corporate mailing address for Mr. Silva and other BioRestorative Therapies executives is 40 MARCUS DRIVE, MELVILLE NY, 11747. BioRestorative Therapies can also be reached via phone at (631) 760-8100 and via email at [email protected]. Learn More on Francisco Silva's contact information.
Has Francisco Silva been buying or selling shares of BioRestorative Therapies?: Francisco Silva has not been actively trading shares of BioRestorative Therapies over the course of the past ninety days. Most recently, on Friday, March 31st, Francisco Silva bought 747 shares of BioRestorative Therapies stock. The stock was acquired at an average cost of $3.56 per share, with a total value of $2,659.32. Following the completion of the transaction, the vice president now directly owns 159,690 shares of the company's stock, valued at $568,496.40. Learn More on Francisco Silva's trading history.
Who are BioRestorative Therapies' active insiders?: BioRestorative Therapies' insider roster includes Lance Alstodt (CEO), and Francisco Silva (VP). Learn More on BioRestorative Therapies' active insiders.

Francisco Silva Insider Trading History at BioRestorative Therapies

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/31/2023	Buy	747	$3.56	$2,659.32	159,690
11/21/2022	Buy	943	$2.62	$2,470.66	166,046
10/11/2022	Buy	806	$3.69	$2,974.14	164,378
8/29/2022	Buy	2,816	$3.21	$9,039.36	163,572
8/26/2022	Buy	2,600	$3.35	$8,710.00	160,756
11/19/2021	Buy	4,000	$6.66	$26,640.00
9/4/2019	Buy	20,955	$0.24	$5,029.20
8/30/2019	Buy	18,000	$0.28	$5,040.00	19,503
8/26/2019	Buy	7,500	$0.27	$2,025.00
8/22/2019	Buy	17,374	$0.26	$4,517.24

Francisco Silva Buying and Selling Activity at BioRestorative Therapies

BioRestorative Therapies Company Overview

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.

Today's Range

Now: $1.45

$1.32

$1.47

50 Day Range

MA: $1.63

$1.38

$1.92

2 Week Range

Now: $1.45

$1.03

$3.67

Volume

40,169 shs

Average Volume

752,249 shs

Market Capitalization

$10.00 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

63.4

Trump won. Buy this coin now.

From Weiss Ratings | Ad

Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.

This could be his favorite coin.

Francisco Silva Biography and Net Worth

What is Francisco Silva's net worth?

How old is Francisco Silva?

What is Francisco Silva's salary?

How do I contact Francisco Silva?

Has Francisco Silva been buying or selling shares of BioRestorative Therapies?

Who are BioRestorative Therapies' active insiders?